Exclusive financial advisor to Hitachi High-Tech Corporation

KPMG Corporate Finance LLC acted as exclusive financial advisor to Hitachi High-Tech Corporation

KPMG Corporate Finance LLC and KPMG FAS Co., Ltd. acted as exclusive investment banking advisor to Hitachi High-Tech Corporation (Hitachi High-Tech or HHT) on its strategic investment in Invivoscribe, Inc. (IVS), a global provider of blood cancer testing kits and services. In addition to cross-border investment banking advisory services, KPMG LLP also provided financial due diligence and tax due diligence services thereby providing a fully integrated and multidisciplinary solution for HHT.

"Invivoscribe is excited by the synergistic opportunities, combining our core expertise in global standardization of tests and bioinformatics, our clinical lab services, and our processes for developing custom companion diagnostics from analytical/clinical validations through international regulatory approvals and commercialization, with Hitachi’s expertise in instrumentation development and manufacturing,” said Jeffrey Miller, CEO and founder of Invivoscribe.

About Hitachi High-Tech

Hitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including the manufacture and sales of clinical analyzers, biotechnology products, analytical instruments, semiconductor manufacturing equipment, and analysis equipment, and providing high value-added solutions in the fields of social and industrial infrastructures and mobility. HHT’s consolidated revenues for FY 2021 were approximately USD 5.1 billion.

About Invivoscribe

Invivoscribe has been improving lives with Precision Diagnostics for more than twenty-five years, advancing the field of precision medicine by developing and selling standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe is engaged in three core business functions: 1) testing services for blood cancers, 2) global sales and distribution of test kits and licensing bioinformatics software, and 3) the development and commercialization of companion diagnostics to support pharmaceutical approval of new oncology treatments.

Meet our team

In today’s market, you need an advisor with objective insight at every step of the transaction process. We work with you throughout the full deal cycle to create value and successfully execute your deal strategy.

Image of Jason Moran
Jason Moran
Managing Director, KPMG Corporate Finance LLC


Trust KPMG Corporate Finance LLC with your next transaction

The global Corporate Finance practice of KPMG International’s network of independent member firms was ranked as the top (#1) M&A middle-market adviser globally by Refinitiv, based on number of completed transactions, for the past 20 years.

Thank you!

Thank you for contacting KPMG. We will respond to you as soon as possible.

Contact KPMG

Use this form to submit general inquiries to KPMG. We will respond to you as soon as possible.

By submitting, you agree that KPMG LLP may process any personal information you provide pursuant to KPMG LLP's Privacy Statement.

An error occurred. Please contact customer support.

Job seekers

Visit our careers section or search our jobs database.

Submit RFP

Use the RFP submission form to detail the services KPMG can help assist you with.

Office locations

International hotline

You can confidentially report concerns to the KPMG International hotline

Press contacts

Do you need to speak with our Press Office? Here's how to get in touch.